Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells

Pediatric Surgery International

Volumn 28, Issue 2, 2012, Pages 149-159

  Lieber, Justus ^a   Ellerkamp, Verena ^a   Wenz, Julia ^a   Kirchner, Bettina ^a   Warmann, Steven W ^a   Fuchs, Jörg ^a   Armeanu Ebinger, Sorin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

ABT 737; Apoptosis sensitizers; BH3 mimetic drugs; HA14 1; Hepatoblastoma; Multidrug resistance; Obatoclax; TW 37

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CDDP; CISPLATIN; DEOXYCORTICOSTERONE ACETATE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; OBATOCLAX; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; ABT-737; BENZAMIDE DERIVATIVE; BENZOPYRAN DERIVATIVE; BIPHENYL DERIVATIVE; ENZYME INHIBITOR; ETHYL 2-AMINO-6-BROMO-4-(1-CYANO-2-ETHOXY-2-OXOETHYL)-4H-CHROMENE-3-CARBOXYLATE; NITRILE; NITROPHENOL; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; SULFONE; TW 37 COMPOUND; TW-37 COMPOUND;

CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; APOPTOSIS; ARTICLE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG RESISTANCE; LIVER TUMOR; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BENZAMIDES; BENZOPYRANS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; NITRILES; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES; SULFONES; TUMOR CELLS, CULTURED;

EID: 84862250352     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-011-2988-z     Document Type: Conference Paper

References (46)

1. Marin JJ, Romero MR, Martinez-Becerra P, Herraez E, Briz O (2009) Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 9(9):1108-1129 (CMM#09)
2. Fuchs J, Rydzynski J, von Schweinitz D, Bode U, Hecker H, Weinel P, Burger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95(1):172-182. doi:10.1002/cncr.10632 (Pubitemid 34743496)
3. Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD (2000) Randomized comparison of cisplatin/vincristine/ fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18(14):2665-2675 (Pubitemid 30463548)
4. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361(17):1662-1670. doi: 10.1056/NEJMoa0810613
5. Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J (2004) Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 40(3):411-421 (S0959804903009328) (Pubitemid 38121279)
6. Warmann S, Gohring G, Teichmann B, Geerlings H, Fuchs J (2002) MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg 37(11):1579-1584 (S0022346802001653)
7. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G (2009) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28(15):2584-2590. doi:10.1200/JCO.2009. 22.4857
8. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15(4):1126-1132. doi:10.1158/1078-0432.CCR-08-0144
9. Chonghaile TN, Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1):S149-S157. doi:10.1038/ onc.2009.52
10. Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ (2009) Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40(6):843-853. doi:10.1016/ j.humpath.2008.10.022
11. Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S (2010) Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer 55(6):1089-1095. doi:10.1002/pbc.22740
12. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74(4):809-818 (Pubitemid 26117140)
13. Doi I (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67(1):1-10
14. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S (2011) Development of a drug resistance model for hepatoblastoma. Int J Oncol 38(2):447-454. doi:10.3892 /ijo.2010.860
15. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621-681. doi:10.1124/ pr.58.3.10
16. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27(50):6398-6406. doi:10.1038/onc.2008.307
17. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97(13):7124-7129 (97/13/7124) (Pubitemid 30431428)
18. Arisan ED, Kutuk O, Tezil T, Bodur C, Telci D, Basaga H (2010) Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 119(2):271-281. doi:10.1007/s10549-009-0343-z
19. Oliver L, Mahe B, Gree R, Vallette FM, Juin P (2007) HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk Res 31(6):859-863. doi:10.1016/j.leukres. 2006.11.010 (Pubitemid 46855902)
20. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'Diaye M, Denoyelle C, Gauduchon P, Poulain L (2009) Mcl-1 is an important determinant of the apoptotic response to the BH3- mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 8(11):3162-3170. doi:10.1158/ 1535-7163.MCT-09-0493
21. Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, Al-Mousa F, Michelangeli F, Thomas DD, Lebien TW, Xing C (2009) Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol 76(3):667-678. doi:10.1124/mol.109.055830
22. Lickliter JD, Wood NJ, Johnson L, McHugh G, Tan J, Wood F, Cox J, Wickham NW (2003) HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 17(11):2074-2080. doi:10.1038/sj.leu.2403102 (Pubitemid 37428370)
23. Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, Geneste O, Gree R, Vallette FM, Juin P (2006) The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66(5):2757-2764. doi:10.1158/0008-5472.CAN-05-2097
24. Niizuma H, Nakamura Y, Ozaki T, Nakanishi H, Ohira M, Isogai E, Kageyama H, Imaizumi M, Nakagawara A (2006) Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 25(36):5046-5055. doi:10.1038/sj.onc. 1209515
25. Pei XY, Dai Y, Grant S (2004) The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther 3(12):1513-1524 (3/12/1513) (Pubitemid 40136706)
26. Doshi JM, Tian D, Xing C (2007) Ethyl-2-amino-6-bromo-4-(1- cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol Pharm 4(6):919-928. doi: 10.1021/mp7000846
27. Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C (2008) sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl- 2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett 259(2):198-208. doi:10.1016/j.canlet.2007.10.012 (Pubitemid 350251643)
28. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49(21):6139-6142. doi:10.1021/jm060460o (Pubitemid 44595187)
29. Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, Nor JE (2009) TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 8(4):893-903. doi:10.1158/1535-7163.MCT-08- 1078
30. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska- Coleska Z, Wang S, Nor JE (2006) Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 66(17):8698-8706. doi:10.1158/0008-5472.CAN-05-3691 (Pubitemid 44449186)
31. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A (2007) Preclinical studies of TW-37, a new nonpeptidic smallmolecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13(7):2226-2235. doi:10.1158/1078-0432. CCR-06-1574 (Pubitemid 46649892)
32. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, Kong D, Wang S, Sarkar FH, Mohammad RM (2008) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 123(4):958-966. doi:10.1002/ijc.23610 (Pubitemid 352032427)
33. Forastiere AA (2008) Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 97(8):701-707. doi:10.1002/jso.21012 (Pubitemid 351812972)
34. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB (2010) The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77(3):483-494. doi:10.1124/mol.109. 060780
35. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT- 737 in acute myeloid leukemia. Cancer Cell 10(5):375-388. doi: 10.1016/j.ccr.2006.10.006 (Pubitemid 44693472)
36. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042): 677-681. doi:10.1038/nature03579 (Pubitemid 40825512)
37. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang D, Wen XY (2007) The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13(2 Pt 1):621-629. doi:10.1158/1078-0432.CCR- 06-1526 (Pubitemid 46225369)
38. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389-399. doi:10.1016/j.ccr.2006.08.027 (Pubitemid 44711953)
39. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM, Dive C, Hickman JA (1999) Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144(5):903-914 (Pubitemid 29238967)
40. E-MEXP-1851 D (http://www.ebi.ac.uk/arrayexpress)
41. Analysis RRDfGE (http://157.82.78.238/refexa/main-search.jsp)
42. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68(9):3413-3420. doi:10.1158/0008-5472.CAN-07-1919
43. Siu WY, Arooz T, Poon RY (1999) Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 250(1):131-141. doi:10.1006/excr.1999.4551 (Pubitemid 29391577)
44. Langer CJ, Albert I, Kovacs P, Blakely LJ, Pajkos G, Petrov P, Somfay A, Szczesna A, Zatloukal P, Kazarnowicz A, Moezi MM, Schreeder MT, Schnyder J, Berger MS (2011) A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol 29 (suppl; abstr 7001)
45. Cvitkovic E (1998) Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24(4):265-281 (Pubitemid 28488281)
46. von Schweinitz D, Byrd DJ, Hecker H, Weinel P, Bode U, Burger D, Erttmann R, Harms D, Mildenberger H (1997) Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 33(8):1243-1249 (S0959804997000956)